Overview: CLL-Specific Rearrangements TestIntroduction: The CLL-Specific Rearrangements Test tests for genetic changes specific to chronic lymphocytic leukemia (CLL), helping diagnose or monitor this cancer causing fatigue or swollen lymph nodes. Affecting 1 in 50,000 people annually, CLL poses diagnostic challenges due to its indolent nature. Following 2023 National Comprehensive Cancer Network (NCCN) guidelines, it uses FISH/PCR for high accuracy, supporting cytogenetics screening. This test is essential for diagnosis, therapy selection, and improving outcomes in oncology.
Other Names: CLL Genetic Test, CLL Rearrangement Assay.
FDA Status: Laboratory-developed test (LDT), meeting cytogenetics standards for diagnostic reliability.
Historical Milestone: Genetic testing for CLL began in the 1990s with research by Döhner, who identified key rearrangements. FISH/PCR advancements in the 2000s by Abbott improved detection, surpassing earlier karyotyping methods.
Purpose: Detects CLL-specific rearrangements to diagnose or monitor CLL, guides targeted therapy, and evaluates patients with fatigue, aiming to improve survival.
Test Parameters: CLL-specific genetic rearrangements
Pretest Condition: No special preparation required. Collect whole blood or bone marrow. Report history of cancer symptoms.
Specimen: Whole Blood (EDTA, 3-5 mL), Bone Marrow (EDTA, 1-3 mL); 4 mL whole blood in Na Heparin tube or bone marrow in sterile container. Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not recommended
Medical History: Document fatigue or swollen lymph nodes. Include current medications or cancer history.
Consent: Written consent required, detailing the test's purpose, cancer risks (e.g., metastasis), and sample collection risks.
Procedural Considerations: Uses FISH/PCR to detect rearrangements, requiring labs with fluorescent microscopes or thermal cyclers. Results available in 5-7 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample degradation or contamination can affect results. Prior treatments may alter detection, requiring correlation.
Clinical Significance: Positive rearrangements confirm CLL, guiding therapy. Early treatment might improve survival, while untreated cases lead to death. Normal results may require additional genetic tests.
Specialist Consultation: Consult an oncologist for interpretation.
Additional Supporting Tests: Lymph node biopsy, flow cytometry, or IGHV mutation test to confirm diagnosis.
Test Limitations: Specific to CLL; correlation with other markers needed. False negatives possible with degraded samples.
References: NCCN Guidelines, 2023; Blood, Döhner H, 2022.
